tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Blueprint Medicines price target raised to $129 from $88 at UBS

UBS analyst David Lai raised the firm’s price target on Blueprint Medicines (BPMC) to $129 from $88 and keeps a Neutral rating on the shares after Sanofi (SNY) announced its intention to acquire Blueprint for up to $9.5B including a contingent value right.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1